Identification of a New Metabolite of Furosemide in Humans (PYPARK)

Henri Mondor University Hospital

Status: Completed

Conditions: Treatment by Furosemide

Treatments: Other: Not intervention

Study type: Observational

Funder types: Other

Identifiers

NCT02872168

2014-A01789-38

Details and patient eligibility

About

Recent in-vitro and in-vivo studies performed by one of the investigators (ESO, ICMPE, UPEC, France) have recently allowed to synthetize a new and easy-to-synthesized chemical compound of the furosemide (pyridinium furosemide) during furosemide degradation by electro-Fenton or bioconversion. The biological properties of pyridinium furosemide are currently under investigation. Furosemide is a diuretics currently used in the treatment of patients with heart failure. The goal of the investigators is to assay pyridinium furosemide in urine of patients treated by furosemide to demonstrate that pyridinium is or not a metabolite of furosemide in humans. This study will contribute to assess the fate of pharmaceutical residues of furosemide in the environment.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥ 18 years
2. Written informed consent
3. Affiliation to social security
4. Known heart failure
5. Treatment by furosemide

Exclusion criteria

None